Loading organizations...
Key people at ARGOBIO.
ARGOBIO is a Paris, France-based startup studio that identifies, incubates, and launches early-stage biotechnology companies derived from innovative European academic research institutions. The firm focuses on developing novel therapeutics for rare diseases, neurological disorders, oncology, and immunology by providing operational support, translational research, and preclinical testing up to Series A funding. Operating with €50 million in committed capital, the venture builder aims to create at least five breakthrough therapeutic spinouts over a five-year period. The organization is backed by a syndicate of institutional and corporate investors, including Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and the Institut Pasteur. Its growing portfolio of incubated spinouts includes Crucible Therapeutics, Laigo Bio, and Enodia Therapeutics, which target conditions like frontotemporal dementia. ARGOBIO was founded in 2021 by Kurma Partners and Bpifrance, with executive leadership including Rémi Soula and Thierry Laugel.
Key people at ARGOBIO.
ARGOBIO has 1 tracked investment across 1 company. The latest tracked deal is $636.0M Seed Extension in Laigo Bio in March 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 23, 2026 | Laigo Bio | $636.0M Seed Extension | Biovance Capital, Kurma Partners | Angelini Ventures, Cancer Research Horizons, Curie Capital, Eurazeo, Oncode Oncology Bridge Fund, ROM Utrecht Region |
Argobio is a European biotech startup studio that sources early-stage projects from academic institutions to build and launch breakthrough therapeutic companies, targeting rare diseases, neurological disorders, oncology, and immunology.[1][3][4] Launched with €50 million in committed capital, it has already created a portfolio of eight companies, providing incubation, entrepreneurial leadership, and operational support up to significant financing milestones, such as seed rounds for spinouts like Laigo Bio (€11.5M in December 2025) and Elkedonia (€11.25M in June 2025).[2][4] Its investment philosophy emphasizes translating cutting-edge European academic science into globally competitive biotechs through hands-on venture building, strong investor syndicates, and expertise in drug development.[3][4]
Argobio was launched in 2021 by Kurma Partners, a leading healthcare VC firm, and Bpifrance, France's public investment bank, with €50 million in committed capital from strategic partners including Angelini Pharma, Evotec, and Institut Pasteur.[3][6] Key leaders include Yves Ribeill, Neill Mackenzie, and Rémi Soula as the core team, with Thierry Laugel (Kurma Partners) as President and Laurent Arthaud (Bpifrance) as Chairman of the Supervisory Board.[3] The studio's focus has evolved from an initial goal of launching five biotechs over five years to actively building eight portfolio companies by 2025, starting with investments like Crucible Therapeutics (2023) and accelerating with recent launches like Elkedonia and Laigo Bio.[1][2][4]
Argobio rides the wave of targeted protein degradation (TPD) and neuroplastogen therapeutics, addressing "undruggable" targets in oncology, immunology, and neurological disorders amid rising demand for precision medicines.[2][4][5] Its timing aligns with Europe's push for biotech sovereignty, bridging academic research gaps through tech transfer and attracting syndicates that amplify Northern and Western European innovation hubs like Sheffield, Utrecht, and Paris.[1][2][4] By validating early academic spinouts—e.g., Elkedonia's non-addictive depression treatments and Laigo Bio's membrane protein tech—Argobio influences the ecosystem by accelerating clinical translation, fostering investor confidence in high-risk areas, and scaling Europe's role in global biotech against US dominance.[3][5]
Argobio's momentum positions it to exceed its original five-company goal, with recent 2025 launches signaling a scalable model for 10+ portfolio firms amid booming TPD and neuroscience funding.[2][4] Trends like AI-driven drug discovery and immunology expansion will shape its path, potentially driving IND filings for leads like SureTAC™ or Elkedonia's neuroplastogens by 2027.[2][5] Its influence may evolve into a pan-European biotech factory, deepening academic-VC ties and yielding exits or IPOs that reinforce Europe's therapeutic innovation edge—turning raw science into patient-impacting breakthroughs, just as its €50M launch promised.[3][6]
